Key result
High-risk 10-cuproptosis-related lncRNA signature linked to shorter overall survival in colon adenocarcinoma.
Why the study?
The role and prognostic value of cuproptosis-related lncRNAs in colon adenocarcinoma remained unknown.
Observational (n=446)
A 10-cuproptosis-related lncRNA signature can independently predict overall survival and drug sensitivity in colon adenocarcinoma patients.
Answers are grounded in this paper and cite their sources.
Requires prospective validation before clinical use in colon adenocarcinoma; extends cuproptosis-lncRNA research but remains hypothesis-generating.
Background Cuproptosis, a newly identified form of programmed cell death, is thought to play a role in tumorigenesis. Long non-coding RNAs (lncRNAs) are reported to be associated with tumor progression and prognosis in colon adenocarcinoma (COAD). However, the role and prognostic value of cuproptosis-related lncRNAs in COAD remains unknown. This study is devoted to constructing and validating a cuproptosis-related lncRNA signature that can predict COAD patient outcomes using bioinformatics methods. Methods The COAD mRNA and lncRNA expression profiles and corresponding clinical data were downloaded from The Cancer Genome Atlas (TCGA) database and 2,567 cuproptosis-related lncRNAs were obtained. A 10 cuproptosis-related-lncRNA prognostic signature was then constructed using the least absolute shrinkage and selection operator (LASSO) algorithm and Cox regression model and patients were divided into high- and low-risk groups. Kaplan-Meier analysis, receiver operating characteristic (ROC) curve, and a nomogram were employed to evaluate the predictive power of the signature. The immune characteristics and drug sensitivity were also investigated based on the signature. Quantitative reverse transcription polymerase chain reaction (qRT-PCR) was performed to verify the risk model. In vitro experiments were conducted to validate the expression of the ten lncRNAs during cuproptosis. Results The high-risk group was associated with shorter overall survival (OS) time in COAD patients (p<0.001). Multivariate Cox regression indicated that a high-risk score was an independent risk factor for poor prognosis (p<0.001). ROC curve analysis was performed to confirm the validity of the signature (area under the curve (AUC) at 3 years: 0.879). Gene Ontology (GO) enrichment analysis revealed that the signature was highly correlated with the immune response in biological processes. The immune function, the score of the immune cells, and the expression of immune checkpoints were significantly different between the two risk groups. Three drugs, LAQ824, FH535, YM155, were found to be more sensitive in the high-risk group. Finally, the expression levels of the ten lncRNAs comprising the signature were tested by qRT-PCR. Conclusion A ten-cuproptosis-related lncRNA signature was constructed that provided promising insights into personalized prognosis and drug selection among COAD patients.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2022) conducted an observational in Colon adenocarcinoma (n=446). High-risk score based on a 10-cuproptosis-related lncRNA signature vs. Low-risk score was evaluated on Overall survival (p=<0.001). A high-risk score derived from a 10-cuproptosis-related lncRNA signature was an independent risk factor for shorter overall survival in patients with colon adenocarcinoma.
Synapse has enriched 10 related papers. Consider them for comparative context: